Table 7 Summary of adverse events in the Rifampicin + FHND9041 group (SS)
System organ classification Preferred terminology | Monotherapy Phase with FHND9041 | Monotherapy Phase with Rifampicin | Co-administration phase | Total |
|---|---|---|---|---|
N | 15 | 15 | 14 | 15 |
TEAE | 9 (60.0%)[16] | 2 (13.3%)[3] | 4 (28.6%)[4] | 10 (66.7%)[23] |
Positive Urinary Occult Blood | 0 (0.0%)[0] | 0 (0.0%)[0] | 2 (14.3%)[2] | 2 (13.3%)[2] |
Elevated Blood Myoglobin | 0 (0.0%)[0] | 0 (0.0%)[0] | 2 (14.3%)[2] | 2 (13.3%)[2] |
C Elevated Reactive Proteins | 1 (6.7%)[1] | 0 (0.0%)[0] | 0 (0.0%)[0] | 1 (6.7%)[1] |
Elevated Gamma-Glutamyltransferase | 0 (0.0%)[0] | 1 (6.7%)[1] | 0 (0.0%)[0] | 1 (6.7%)[1] |
Elevated Alanine Aminotransferase | 1 (6.7%)[1] | 0 (0.0%)[0] | 0 (0.0%)[0] | 1 (6.7%)[1] |
Elevated LDL | 0 (0.0%)[0] | 1 (6.7%)[1] | 0 (0.0%)[0] | 1 (6.7%)[1] |
Decreased Lymphocyte Count | 1 (6.7%)[1] | 0 (0.0%)[0] | 0 (0.0%)[0] | 1 (6.7%)[1] |
Positive Urine White Blood Cells | 1 (6.7%)[1] | 0 (0.0%)[0] | 0 (0.0%)[0] | 1 (6.7%)[1] |
Elevated Blood Bilirubin | 1 (6.7%)[1] | 0 (0.0%)[0] | 0 (0.0%)[0] | 1 (6.7%)[1] |
Hypertriglyceridemia | 4 (26.7%)[4] | 0 (0.0%)[0] | 0 (0.0%)[0] | 4 (26.7%)[4] |
Hyperuricaemia | 2 (13.3%)[2] | 0 (0.0%)[0] | 0 (0.0%)[0] | 2 (13.3%)[2] |
Hypercholesterolaemia | 0 (0.0%)[0] | 1 (6.7%)[1] | 0 (0.0%)[0] | 1 (6.7%)[1] |
Upper Respiratory Tract Infection | 1 (6.7%)[1] | 0 (0.0%)[0] | 0 (0.0%)[0] | 1 (6.7%)[1] |
Have A High Temperature | 1 (6.7%)[1] | 0 (0.0%)[0] | 0 (0.0%)[0] | 1 (6.7%)[1] |
Haematuria | 1 (6.7%)[1] | 0 (0.0%)[0] | 0 (0.0%)[0] | 1 (6.7%)[1] |
Oral Mucositis | 1 (6.7%)[1] | 0 (0.0%)[0] | 0 (0.0%)[0] | 1 (6.7%)[1] |
Anemic | 1 (6.7%)[1] | 0 (0.0%)[0] | 0 (0.0%)[0] | 1 (6.7%)[1] |